Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 Par Value
-
Shares outstanding
-
27.9M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
20.2M
-
Shares change
-
+7.64M
-
Total reported value, excl. options
-
$47.8M
-
Value change
-
+$13.4M
-
Put/Call ratio
-
0.61
-
Number of buys
-
31
-
Number of sells
-
-37
-
Price
-
$2.38
Significant Holders of Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value (JSPR) as of Q3 2025
83 filings reported holding JSPR - Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value as of Q3 2025.
Jasper Therapeutics, Inc. - Common Stock, $0.001 Par Value (JSPR) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.2M shares
of 27.9M outstanding shares and own 72.21% of the company stock.
Largest 10 shareholders include Velan Capital Investment Management LP (2.67M shares), Soleus Capital Management, L.P. (1.49M shares), ACORN CAPITAL ADVISORS, LLC (1.38M shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (1.32M shares), Rock Springs Capital Management LP (1.1M shares), Carlyle Group Inc. (1.07M shares), Woodline Partners LP (1.04M shares), VANGUARD GROUP INC (1.03M shares), Propel Bio Management, LLC (1.03M shares), and T. Rowe Price Investment Management, Inc. (1.03M shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.